This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OBLN vs. RVP, VVOS, NXGL, XAIR, NEPH, ALUR, DHAI, CODX, INBS, and ICUShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Retractable Technologies (RVP), Vivos Therapeutics (VVOS), NEXGEL (NXGL), Beyond Air (XAIR), Nephros (NEPH), Allurion Technologies (ALUR), DIH Holding US (DHAI), Co-Diagnostics (CODX), Intelligent Bio Solutions (INBS), and SeaStar Medical (ICU). Obalon Therapeutics vs. Retractable Technologies Vivos Therapeutics NEXGEL Beyond Air Nephros Allurion Technologies DIH Holding US Co-Diagnostics Intelligent Bio Solutions SeaStar Medical Retractable Technologies (NYSE:RVP) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking. Does the media favor RVP or OBLN? In the previous week, Retractable Technologies had 6 more articles in the media than Obalon Therapeutics. MarketBeat recorded 6 mentions for Retractable Technologies and 0 mentions for Obalon Therapeutics. Retractable Technologies' average media sentiment score of 0.51 beat Obalon Therapeutics' score of 0.00 indicating that Retractable Technologies is being referred to more favorably in the media. Company Overall Sentiment Retractable Technologies Positive Obalon Therapeutics Neutral Do insiders and institutionals hold more shares of RVP or OBLN? 7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 55.0% of Retractable Technologies shares are owned by company insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, RVP or OBLN? Retractable Technologies has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, meaning that its stock price is 223% less volatile than the S&P 500. Which has better earnings and valuation, RVP or OBLN? Retractable Technologies has higher revenue and earnings than Obalon Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRetractable Technologies$38.27M0.54-$7.01M-$0.41-1.69Obalon Therapeutics$1.59M2.84-$12.33MN/AN/A Does the MarketBeat Community prefer RVP or OBLN? Obalon Therapeutics received 246 more outperform votes than Retractable Technologies when rated by MarketBeat users. Likewise, 46.95% of users gave Obalon Therapeutics an outperform vote while only 0.00% of users gave Retractable Technologies an outperform vote. CompanyUnderperformOutperformRetractable TechnologiesOutperform VotesNo VotesUnderperform Votes89100.00% Obalon TherapeuticsOutperform Votes24646.95% Underperform Votes27853.05% Is RVP or OBLN more profitable? Retractable Technologies has a net margin of -41.11% compared to Obalon Therapeutics' net margin of -776.76%. Retractable Technologies' return on equity of -17.15% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Retractable Technologies-41.11% -17.15% -9.33% Obalon Therapeutics -776.76%-161.38%-83.58% SummaryRetractable Technologies beats Obalon Therapeutics on 9 of the 14 factors compared between the two stocks. Remove Ads Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.51M$4.27B$5.54B$7.49BDividend YieldN/A48.05%5.35%4.04%P/E Ratio-0.3328.6923.2518.07Price / Sales2.8445.73361.2686.80Price / CashN/A51.0838.1634.64Price / Book0.755.906.493.99Net Income-$12.33M$67.64M$3.21B$247.18M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$0.45-71.7%N/A+841.9%$4.51M$1.59M-0.332Analyst ForecastGap DownHigh Trading VolumeRVPRetractable TechnologiesN/A$0.75+0.4%N/A-37.4%$22.55M$38.27M-1.39240Gap DownVVOSVivos Therapeutics2.5961 of 5 stars$3.71+3.1%$6.30+69.8%-24.1%$21.85M$14.58M-0.65160Earnings ReportNXGLNEXGEL0.7174 of 5 stars$3.09+14.4%N/A+19.7%$20.98M$6.73M-5.3310Upcoming EarningsGap UpXAIRBeyond Air4.3245 of 5 stars$0.28+5.6%$3.67+1,194.3%-84.1%$19.49M$3.02M-0.2770NEPHNephros1.3808 of 5 stars$1.60+2.9%$5.00+213.5%-7.7%$16.82M$14.16M-17.7230Gap UpALURAllurion Technologies3.0849 of 5 stars$3.43-4.2%$22.83+565.7%-92.9%$16.44M$34.75M-0.29501Short Interest ↑Analyst RevisionGap DownHigh Trading VolumeDHAIDIH Holding US1.0303 of 5 stars$0.32-17.8%N/A-78.6%$15.29M$64.47M-1.08N/AHigh Trading VolumeCODXCo-Diagnostics3.4681 of 5 stars$0.46+0.6%$1.50+223.6%-67.2%$14.80M$7.32M-0.34100Earnings ReportGap UpINBSIntelligent Bio Solutions0.5817 of 5 stars$2.11-2.3%N/A-61.7%$14.30M$3.03M0.0010ICUSeaStar Medical0.5889 of 5 stars$2.18-1.8%N/A-92.8%$14.11M$68,000.00-0.192Earnings ReportGap Up Remove Ads Related Companies and Tools Related Companies RVP Competitors VVOS Competitors NXGL Competitors XAIR Competitors NEPH Competitors ALUR Competitors DHAI Competitors CODX Competitors INBS Competitors ICU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBLN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBLN Stock Free OBLN Stock Alerts